Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies

Project description

Is it possible to reverse fibrosis?

When there is injury or damage to an organ, the normal healing process involves the formation of new tissue. When this process becomes dysregulated, it leads to the formation of excessive fibrous connective tissue causing fibrosis. Funded by the European Research Council, the Rewind-MF project focuses on primary myelofibrosis, a blood malignancy associated with the activation of fibrosis-driving cells in the bone marrow. The study explores the reversibility of fibrosis, particularly in cases where allogeneic stem cell transplantation is not a viable option. By delving into the mechanisms of reversing fibrosis, researchers expect to identify therapeutic targets and understand how blood cancer is sustained in the bone marrow.

Objective

Fibrosis is estimated to be involved in 45% of global mortality, and currently no specific therapies for fibrosis in most organs exist. One central and controversially discussed question in the field of organ fibrosis is: is fibrosis truly reversible? In Rewind-MF, I will address this biologically and clinically highly relevant question in a prime example: bone marrow fibrosis in a chronic blood cancer called Primary Myelofibrosis (PMF). In PMF, hematopoietic stem cells become mutated and activate fibrosis-driving cells. Fibrosis reversal in PMF is possible through allogeneic stem cell transplant (ASCT). However, the majority of patients are not eligible for this high-risk procedure. Alternative fibrosis-reversing strategies are not available, leaving this patient group without any treatment option.

My specific aims in Rewind-MF are: (1) to gain spatio-temporal insights into fibrosis reversal and mutant clone elimination mechanisms to predict, which patients will benefit from ASCT, and to identify therapeutic targets; (2) to understand how blood cancer is maintained in the bone marrow and later the spleen stroma in order to find new ways to reverse fibrosis, and eradicate the cancer cells, and (3) to validate fibrosis reversal mechanisms and translate them into clinically relevant therapeutic strategies.

What makes Rewind-MF unique is the holistic bench-to-bedside approach starting from a stem cell biological hypothesis [tested by innovative murine models and (stem) cell approaches], advanced by a broad interdisciplinary expertise with novel single cell, spatial genomic and computational technologies, to dissect mechanisms of fibrosis reversal and develop therapeutic approaches which go beyond pure target identification. The integration of all these technologies in clinically relevant specimens with follow-up data and large independent validation cohorts will truly revolutionize the prognostication and (personalized) treatment of patients with MF.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

UNIVERSITAETSKLINIKUM AACHEN
Net EU contribution
€ 1 999 313,00
Address
Pauwelsstrasse 30
52074 Aachen
Germany
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 313,00

Beneficiaries (1)